ArticleAlzheimer's research & therapy2019
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.
Article in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.Frontiers in aging neuroscience · 2021Pooled it
- Depressive Symptoms in the Elderly-An Early Symptom of Dementia? A Systematic Review.Frontiers in pharmacology · 2020Pooled it
- CogStrat: web-based tools for predicting incident cognitive impairment in cognitively normal older adults.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.Neurology · 2026Observational
- Differences in retroactive interference response reveal sex-specific memory resilience in pre-symptomatic triple transgenic Alzheimer's disease mice.Brain communications · 2026Article
- Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly.Alzheimer's research & therapy · 2025Article
- Understanding the role of microglia in Alzheimer's disease: insights into mechanisms, acupuncture, and potential therapeutic targets.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Review
- Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Subjective Cognitive Decline in Community-Dwelling Older Adults With Objectively Normal Cognition: Mediation by Depression and Instrumental Activities of Daily Living.Psychiatry investigation · 2024Article
- Cerebral Amyloidosis in Individuals with Subjective Cognitive Decline: From Genetic Predisposition to Actual Cerebrospinal Fluid Measurements.Biomedicines · 2024Article
- A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer's Spectrum Disorders.Journal of psychiatry and brain science · 2024Article
- Multipredictor risk models for predicting individual risk of Alzheimer's disease.Journal of translational medicine · 2023Article
- Follow-up of participants with subjective cognitive decline from Tremembé epidemiologic study, Brazil.Dementia & neuropsychologia · 2023Article
- Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Life satisfaction across the entire trajectory of Alzheimer's disease: A mediation analysis.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- The missing X factor in Alzheimer disease.Nature reviews. Neurology · 2021Article
- Dementia risk communication. A user manual for Brain Health Services-part 3 of 6.Alzheimer's research & therapy · 2021Review
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.The Lancet. Neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundBiomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular relevant for individuals who present at a memory clinic, but are deemed cognitively normal. The objective of the current study is to construct biomarker-based prognostic models for personalized risk of clinical progression in cognitively normal individuals presenting at a memory clinic.
methodsWe included 481 individuals with subjective cognitive decline (SCD) from the Amsterdam Dementia Cohort. Prognostic models were developed by Cox regression with patient characteristics, MRI, and/or CSF biomarkers to predict clinical progression to MCI or dementia. We estimated 5- and 3-year individualized risks based on patient-specific values. External validation was performed on Alzheimer's Disease Neuroimaging Initiative (ADNI) and an European dataset.
resultsBased on demographics only (Harrell's C = 0.70), 5- and 3-year progression risks varied from 6% [3-11] and 4% [2-8] (age 55, MMSE 30) to 38% [29-49] and 28% [21-37] (age 70, MMSE 27). Normal CSF biomarkers strongly decreased progression probabilities (Harrell's C = 0.82). By contrast, abnormal CSF markedly increased risk (5 years, 96% [56-100]; 3 years, 89% [44-99]). The CSF model could reclassify 58% of the individuals with an "intermediate" risk (35-65%) based on the demographic model. MRI measures were not retained in the models.
conclusionThe current study takes the first steps in a personalized approach for cognitively normal individuals by providing biomarker-based prognostic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.